AI Systems with Advanced Analytics to Identify Unmet Patient Needs

Breast cancer is one of the most common types of cancer found in women worldwide. However, breast cancer does not always show obvious symptoms in the early stages. Hence, companies in the breast cancer diagnostics market are increasing their R&D in AI technologies to identify unmet patient needs. For instance, Paragon Biosciences LLC announced the launch of its seventh portfolio company Qlarity Imaging LLC, to gain FDA clearance for their AI system used for breast cancer diagnostics in radiology.

Companies in the breast cancer diagnostics market are harnessing the advantages of AI to improve medical outcomes. The AI technology is being increasingly used in additional image modalities with the goal of lowering costs for hospitals as well as payers. Companies in the market for breast cancer diagnostics are directing their investments in developing AI systems with intuitive displays and machine learning (ML).

breast cancer diagnostics market infographic

To know the scope of our report Get a Sample on Breast Cancer Diagnostics Market

Blood Screening Tests Revolutionize Breast Cancer Diagnostics with Early Detection Possibilities

Most types of breast cancer are treatable and survival rates are high for patients that detect cancer at an early stage. Hence, researchers in the market for breast cancer diagnostics are increasing their focus in novel methods of blood screening that are reinventing techniques for early detection of breast cancer. For instance, researchers from the University of Nottingham are innovating in new blood screening methods that can help detect breast cancer years before it gets severe. Such discoveries are bolstering market growth, as the breast cancer diagnostics market is expected to reach a revenue of ~US$ 9 Bn by the end of 2027. Moreover, molecular testing is anticipated for exponential growth during the forecast period.

On the other hand, researchers are examining antigens and auto-antibodies to determine the presence of a tumor. Tumor-associated antigens (TAAs) are considered as a reliable indicator of breast cancer. Thus, companies in the breast cancer diagnostics market should collaborate with researchers to advance in clinical studies.

Get a glimpse of the in-depth analysis through our Report Brochure

Simplifying Synthesis Steps and Nanoprobe Functionalization Bolster Innovations in Nanotechnology

Nanotechnology holds promising potential for early detection of breast cancer. This technology is being highly publicized for its high sensitivity, specificity, and multiplexed measurement capacity in the breast cancer diagnostics market. However, translation of nanotechnology-based diagnostic methods into routine clinical applications poses as a challenge for healthcare providers.

The breast cancer diagnostics market is consolidated with three major players accounting for ~66% of the global market share. This indicates that companies are increasing their research efforts in new diagnostic methods such as nanotechnology and deep learning to improve clinical numbers. However, the reliability of nanotechnology-based cancer diagnosis in regular clinical practices is still at the nascent stage in the market for breast cancer diagnostics. Moreover, high costs associated with the long-term storage of nanoprobes that are highly sensitive is another barrier for market growth. Hence, companies in the market for breast cancer diagnostics are simplifying the synthesis steps and nanoprobe functionalization and are increasing R&D to launch cost-efficient ways of introducing nanotechnology-based diagnosis in clinical practices.

Automated Diagnosis Techniques with ML Algorithms Help Distinguish Tumors

Automated breast cancer diagnostics based on ML algorithms are bringing about a change in the market landscape. Soft computing techniques are being increasingly used to produce accurate and faster diagnosis of breast cancer amongst patients. Hence, healthcare companies in the breast cancer diagnostics market are collaborating with researchers to combine imaging techniques with ML algorithms to increase diagnosis accuracy. Preprocessing, feature extraction, and classification are becoming the key focus points for healthcare companies in order to advance in ML-based imaging techniques.

Several data mining and ML techniques are being used to facilitate careful interpretation and analysis of peripheral areas of the patient. As such, feature extraction plays a pivotal role in breast cancer detection using ML techniques. Such novel techniques are helping practitioners in the breast cancer diagnostics market to distinguish between benign and malignant tumors. Transform-based texture analysis techniques are being facilitated to convert the image into new analysis studies using spatial frequency properties.

breast cancer diagnostics market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report 

Analysts’ Viewpoint

AI-assisted technologies have become the frontrunner for innovations in the breast cancer diagnostics market. Thus, the market is expected to expand at a favorable CAGR of ~7% during the forecast period. Precision medicines and personalized therapies are helping to improve clinical numbers. Since ‘cancer’ is commonly associated as an ‘expensive disease’, healthcare companies are increasing their R&S activities to boost the availability of affordable tests and treatments.

ML techniques are gaining prominence in mammographic imaging of regions of interest (ROIs). However, there is a need for more confined approach toward the detection of cancerous lesions in conventional ML studies. Hence, companies should increase focus in architecture distortion and the detection of bilateral asymmetry to innovate in mammographic imaging.

Breast Cancer Diagnostics Market: Overview

  • The global breast cancer diagnostics market was valued at US$ 4.8 Bn in 2018 and is projected to expand at a high CAGR from 2019 to 2027. High prevalence and increase in incidence rate of breast cancer across the globe and technological advancements in diagnostic techniques are anticipated to fuel the growth of the global breast cancer diagnostics market.
  • Breast cancer is the most common form of cancer observed among women across the globe and accounts for around 12.3% of all the cancer cases reported. Breast cancer starts in breast tissues when the cells in the breast begin to grow out of control.
  • Breast cancer starts in the milk ducts that carry milk to the nipple. It could also start in the milk glands and other tissues of the breast. Symptoms of breast cancer are the formation of new lump or mass in the breast, swelling, pain, and nipple retraction. The two basic types of breast cancer are invasive breast cancer and non-invasive breast cancer. Around 80% of breast cancers are invasive.
  • Breast cancer can be diagnosed using different techniques, from physical examination to CT/PET scan. Mammography systems are used as the first line of diagnosis of breast cancer. The other breast cancer diagnostic tools are breast ultrasound systems, breast magnetic resonance imaging, computed tomography (CT scan), positron emission tomography (PET scan), breast biopsy, and molecular testing.
  • The global breast cancer diagnostics market is expected to be driven by high prevalence and increase in incidence rate of breast cancer across the globe. According to the World Cancer Research Fund Organization, 2,088,849 cases of breast cancer were reported globally in 2018. The organization estimated that the number of breast cancer cases would reach to 5.5 million across the world by the end of 2030.
  • Presently, R&D on cancer diagnosis is primarily focused on liquid biopsy. Market players and research institutes are conducting extensive clinical trials to develop highly sensitive biopsy platform. In May 2018, Grail, a U.S.-based biotechnology company, raised US$ 1 Bn in VC funding and embarked on a 120,000-patient study for early breast cancer detection. Extensive research on biopsy aimed at promoting early diagnosis of cancer is likely to drive the global breast cancer diagnostics market during the forecast period.

Breast Cancer Diagnostics Market: Segmentation

  • The global breast cancer diagnostics market has been segmented based on technique, cancer type, end user, and region
  • In terms of technique, the global breast cancer diagnostics market has been categorized into imaging, breast biopsy tests, and molecular testing. The imaging segment is projected to lead the global breast cancer diagnostics market during the forecast period. Imaging tests are most preferred for the initial diagnosis of breast cancer and are comparatively costlier than other tools. This can be attributed to the segment’s market dominance in 2018. The imaging segment has been classified into mammography systems, breast ultrasound systems, MRI scan, and PET/CT scan.
  • Based on cancer type, the global breast cancer diagnostics market has been bifurcated into ductal carcinoma in situ (DCIS) and invasive breast cancer. The invasive breast cancer segment accounted for the largest share of the global market in 2018 and the trend is anticipated to continue during the forecast period.
  • In terms of end user, the global breast cancer diagnostics market has been divided into hospitals & ambulatory surgery centers, diagnostic laboratories, and research & academic institutes. The hospitals & ambulatory surgery centers segment dominated the global breast cancer diagnostics market in 2018 and the trend is expected to continue from 2019 to 2027.

Breast Cancer Diagnostics Market: Regional Segmentation

  • In terms of region, the global breast cancer diagnostics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • North America dominated the global market in 2018 and is likely to gain market share by the end of 2027. The region’s dominance in terms of market share can be attributed to high prevalence and increase in incidence of breast cancer in the U.S. and Canada, and well-established healthcare facilities. High per capita healthcare expenditure, favorable medical reimbursement policies, and early adoption of technologically advanced products are attributed to the region’s large share of the global breast cancer diagnostics market in 2018.
  • Asia Pacific is projected to be the fastest growing market for breast cancer diagnostics during the forecast period. Japan dominated the market in the region in 2018. The market in India is anticipated to expand at a high CAGR during the forecast period.
  • The breast cancer diagnostics market in Latin America and Middle East & Africa is expected to expand at a high CAGR, owing to increase in demand for early diagnosis of breast cancer and focus of manufacturers on addressing unmet medical needs.

Breast Cancer Diagnostics Market: Major Players

  • Companies such as Siemens Healthineers, GE Healthcare, and Hologic, Inc. accounted for major share of the global breast cancer diagnostics market in 2018. Other global players in the market include
    • Abbott Laboratories
    • Koninklijke Philips N.V., C. R. Bard, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Fujifilm Holding Corporation
    • Leica Biosystems Nussloch GmbH
    • bioTheranostics, Inc.
    • Myriad Genetics, Inc.
  • These players focus on adopting organic and inorganic growth strategies to strengthen product portfolio. These companies have adopted strategies such as collaborations & acquisitions, expansion of geographic footprint, investment in research & development, and manufacture of novel breast cancer diagnostic tools in order to be competitive in the global breast cancer diagnostics market.

Breast Cancer Diagnostics Market - Scope of the Report

TMR’s report on the global breast cancer diagnostics market studies the past as well as current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period from 2019 to 2027. The report provides the revenue of the global breast cancer diagnostics market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global breast cancer diagnostics market for the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global breast cancer diagnostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have also employed a combination of top-down and bottom-up approaches to study various phenomena in the global breast cancer diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competitive dynamics in the global breast cancer diagnostics market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the global breast cancer diagnostics market. The next section of the global breast cancer diagnostics market report highlights the USPs, which include technological advancements and breast cancer epidemiology.

The report also delves into the competitive landscape of the global breast cancer diagnostics market. Key players operating in the global breast cancer diagnostics treatment market have been identified, and each one of these has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the global breast cancer diagnostics treatment market report.

Key Questions Answered in Global Breast Cancer Diagnostics Market Report

  • What is the sales/revenue generated by different breast cancer diagnostics across all the regions during the forecast period?
  • What are the major drivers, restraints, and opportunities in the global market?
  • Which region is set to expand at the fastest CAGR during the forecast period?
  • Which segment will have the highest revenue globally in 2027 and which product will expand at the fastest CAGR during the forecast period?

Breast Cancer Diagnostics Market - Research Objectives and Approach

The comprehensive report on the global breast cancer diagnostics market begins with an overview of the market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives of the study and healthcare compliances laid down by accredited agencies in the purview of research in the global breast cancer diagnostics market. It is followed by market introduction, market dynamics, and an overview of the global breast cancer diagnostics market, which includes TMR analysis of market drivers, restraints, and trends affecting the growth of the market. Furthermore, Y-o-Y analysis with elaborate insights has been provided to understand the Y-o-Y trends of the breast cancer diagnostics market. The next section of the global breast cancer diagnostics market report highlights the USPs, including technological advancements and breast cancer epidemiology in the global breast cancer diagnostics market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

Revenue generated by key breast cancer diagnostics manufacturers has been mapped to ascertain the size of the global breast cancer diagnostics market in terms of value. The forecast presented here assesses the total revenue generated by breast cancer diagnostics. In order to provide an accurate forecast, we took into consideration the parent cancer diagnostics market.

The report analyzes the global breast cancer diagnostics market in terms of technique, cancer type, end user, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2027 has been provided. These valuable insights would help market stakeholders in making informed business decisions for investments in the breast cancer diagnostics market.

Breast Cancer Diagnostics Market – Segmentation

Technique

Imaging

  • Mammography
  • Analog Mammography
  • Digital Mammography
  • Breast Ultrasound System
  • MRI Scan
  • PET/CT Scan

Tissue Biopsy Tests

Molecular Testing

Cancer Type

Ductal Carcinoma In Situ (DCIS)

Invasive Breast Cancer

  • Invasive Ductal Carcinoma
  • Invasive Lobular Carcinoma
  • Metastatic Breast Cancer
  • Others

End User

Hospitals & Ambulatory Surgery Centers

Diagnostic Laboratories

Research & Academic Institutes

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Breast Cancer Diagnostics Market

Buy Now